PLAC1 and cancer: To pursue potential application of anti-PLAC1 antibodies for cancer immunotherapy, we developed an anti-PLAC1-ADC and assessed its potential efficacy in three human prostate cancer cell lines, namely LNCaP, DU145, and PC3.